L
Lars Ståhle
Researcher at Karolinska University Hospital
Publications - 99
Citations - 5504
Lars Ståhle is an academic researcher from Karolinska University Hospital. The author has contributed to research in topics: Microdialysis & Apomorphine. The author has an hindex of 40, co-authored 99 publications receiving 5260 citations. Previous affiliations of Lars Ståhle include AstraZeneca & Karolinska Institutet.
Papers
More filters
Journal ArticleDOI
Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation
TL;DR: It is concluded that conversion into 24S-hydroxycholesterol is a quantitatively important mechanism for elimination of cholesterol from human brain and suggests that the liver is the major eliminating organ.
Journal ArticleDOI
Partial least squares analysis with cross‐validation for the two‐class problem: A Monte Carlo study
Lars Ståhle,Svante Wold +1 more
TL;DR: In this paper, a method for statistical analysis of two independent samples with respect to difference in location is investigated, using the partial least squares projections to latent structures (PLS) with cross-validation.
Journal ArticleDOI
AAPS-FDA Workshop White Paper: Microdialysis Principles, Application and Regulatory Perspectives
Chandra S. Chaurasia,Markus Müller,Edward D. Bashaw,Eva Benfeldt,Jan Bolinder,Ross Bullock,Peter M. Bungay,Elizabeth C. M. DeLange,Hartmut Derendorf,William F. Elmquist,Margareta Hammarlund-Udenaes,Christian Joukhadar,Dean L. Kellogg,Craig E. Lunte,Carl-Henrik Nordström,Hans Rollema,Ronald J. Sawchuk,Belinda W.Y. Cheung,Vinod P. Shah,Lars Ståhle,Urban Ungerstedt,Devin F. Welty,Helen Yeo +22 more
TL;DR: Although μD as a preclinical and clinical tool has been available for two decades, there is still uncertainty about the use of μD in drug research and development, both from a methodological and a regulatory point of view.
Journal ArticleDOI
High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C.
TL;DR: In conclusion, a high dose of ribavirin according to an individualized schedule is feasible but associated with more frequent and serious side effects such as anemia, and the viral response merits further evaluation.
Journal ArticleDOI
Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz.
Jue Wang,Anders Sönnerborg,Anders Rane,Filip Josephson,Stefan Lundgren,Lars Ståhle,Magnus Ingelman-Sundberg +6 more
TL;DR: A novel CYP2B6*16 allele causing less expression of the corresponding enzyme was identified and found to influence the metabolism of efavirenz in vivo, a finding that is of potential impact for anti-HIV therapy in black populations.